ELV

QRFT · Weight decrease · 2d

ELEVANCE HEALTH, INC. (ELV) recently traded at $404.07, placing it at 95% of its 52-week high of $424.43, following 30-day and 90-day returns of +8.4% and +18.6% respectively. Qraft Technologies' AI, managing QRFT's broad large-cap core portfolio by evaluating traditional factors alongside proprietary alternative-data overlays, governs allocations for its ~300 US large-cap holdings. As ELV approached this upper price range, the AI system, evaluating the stock's valuation metrics such as its PER of 16.45 and PBR of 1.78 relative to its rapid ascent, adjusted its position. This analysis, combined with alternative data inputs, triggered consecutive weight decreases from 0.21% to 0.19% within QRFT on June 10th and 11th, reflecting the fund's weekly rebalancing mechanism reacting to perceived shifts in attractiveness at current price levels.

weight 0.210% → 0.190% (-0.020 pp)·stock up 1.5% in the 30 days before

Jun 11·entry $399.18·now $382.23

AIEQ · Weight decrease · 2d

AIEQ initiated a gradual, consecutive decrease in its allocation to Elevance Health, moving from a stable 0.1100% to successive reductions at 0.1000% and 0.0900%. This measured adjustment in ELV's weight follows a -8.9% 30-day return, occurring while the stock trades at 87% of its 52-week high, which aligns with AIEQ's daily rebalancing and high-turnover strategy. The fund's IBM Watson NLP engine likely detected a shift in market sentiment or short-term fundamental signals from news and social posts, despite the company's 16.3 PER and 1.78 PBR. Such a precise, stepped reduction by Amplify ETFs reflects EquBot's risk overlay acting swiftly on dynamic input, rather than a broad re-evaluation of the company's longer-term 6.27% revenue growth or 11.24% ROE.

weight 0.110% → 0.090% (-0.020 pp)·stock down 6.2% in the 30 days before

Jul 17·entry $373.11·now $382.23

AIEQ · Exit · 1d

ELEVANCE HEALTH, INC. exhibited a 9.44% revenue growth and 11.95% ROE, paired with a 16.29 PER and 1.78 PBR, which generally align with AIEQ's fundamentals-plus-sentiment hybrid style for broad market exposure. However, the stock’s ascent to $393.19, reflecting a 21.7% gain in the last 30 days and positioning it at 95% of its 52-week high, likely altered its desirability within the portfolio. AIEQ’s daily rebalancing and its IBM Watson NLP-driven analysis of ELV across various data sources likely indicated that, at this higher valuation, better risk-adjusted opportunities existed elsewhere. The subsequent removal of ELV from the portfolio on 2026-05-30 exemplifies the fund's high-turnover strategy in response to dynamic market conditions.

weight 0.180% → 0 (exited)·stock up 4.4% in the 30 days before

May 30·entry $402.66·now $382.23

LQAI · Exit · 1d

ELEVANCE HEALTH, Inc. presented core financial metrics including a PER of 16.25, PBR of 1.78, 9.44% revenue growth, and an 11.95% ROE, which typically align with LQAI's mandate for large-cap core holdings based on Qraft AI ranking. However, just prior to its removal from the portfolio on 2026-06-09, the stock’s current price of $424.43 reached 100% of its 52-week high, following a substantial 17.0% return over 30 days and 22.8% over 90 days. This rapid appreciation likely prompted the LG-Qraft collaboration's AI engine to re-evaluate ELV against its "core large-cap" selection framework, which avoids heavy factor tilts toward concentrated momentum. The AI system, rebalancing weekly for LQAI, appears to have determined that ELV's valuation had stretched beyond what was suitable for a balanced, AI-driven core position, leading to its complete exit on June 9, 2026.

weight 0.150% → 0 (exited)·stock up 12.3% in the 30 days before

Jun 9·entry $424.43·now $382.23